MUMBAI, India, Aug. 1 -- Intellectual Property India has published a patent application (202441005396 A) filed by Dr. Satya Kumar Avula, Hyderabad, Telangana, on Jan. 26, 2024, for 'synthesis of novel triterpene triazole derivatives of boswellic acid: a potential anti-breast cancer drugs.'
Inventor(s) include Dr. Satya Kumar Avula; Najeeb Ur Rehman; and Ahmed Al-Harrasi.
The application for the patent was published on Aug. 1, under issue no. 31/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a synthesis of 23 new pentacyclic triterpene amides (3a-3l) and 1H-1,2,3-triazole analogues (5a-5k) of AKBA and evaluated them for human breast cancer (MDA-MB-231) activity. Combining amides and 1H-1,2,3-triazoles with the AKBA moiety is beneficial which exhibited highly potent anti-proliferative activity with IC50 values ranging from 8.1 0.2 to 18.5 0.4 M. Among them, compounds 5a and 5i exhibited exceptional inhibitory potency and were found several times more potent than the parent compounds AKBA. Furthermore, the molecular docking analysis was used to identify the potential drug target of the most potent compounds (5a and 5i) and their binding mechanism with the selected drug target. Overall, this new study can open the way to a medicinal production of triterpene amides and 1H-1,2,3-triazole analogues of AKBA employable as potential anti-breast cancer agents."
Disclaimer: Curated by HT Syndication.
